Monitor the say-on-pay vote outcome and any potential dissent given the underwater option overhang (68% underwater) and the large equity plan request. The redomiciliation to Delaware may lead to future governance changes. The next catalyst is the 2026 ASM vote on November 12, 2026.
Price Chart
Executive Summary
Wave Life Sciences filed its definitive proxy statement for the 2026 Annual Meeting on November 12, 2026. Key proposals include the election of nine incumbent directors, ratification of KPMG as auditor, approval of an 11,000,000-share increase to the 2021 Equity Incentive Plan, and an advisory say-on-pay vote. The proxy also details the company's redomiciliation from Singapore to Delaware in August 2026, CEO Paul Bolno's total 2025 compensation of $12.3 million (largely equity-driven), and a 135% achievement of 2025 corporate goals driving bonus payouts. The filing is routine governance with no contested items or shareholder proposals, but the significant equity plan dilution request (5.6% of shares outstanding) and the fact that 68% of outstanding stock options are underwater warrant attention.
Key Facts
- Annual meeting scheduled for November 12, 2026, postponed from August due to redomiciliation from Singapore to Delaware completed on August 7, 2026.
- Proposal to increase shares available under the 2021 Equity Incentive Plan by 11,000,000 shares (from 30,950,000 to 41,950,000).
- As of October 1, 2026, 68% of outstanding stock options were underwater, with a weighted-average exercise price of $10.06 vs. a closing price of $3.88 per share.
- CEO Paul Bolno's 2025 total compensation was $12,277,916, including $700,000 salary, $614,250 cash bonus (135% of target), and $10,926,840 in equity awards (grant-date fair value).
- 2025 corporate goals achieved at 135%; CFO Moran and CTO Vargeese received bonuses at 142% of target.
- Last year's say-on-pay vote received over 99% support; no shareholder proposals are on the ballot.
- All nine director nominees are incumbents; no contested elections.
- RA Capital Management, L.P. beneficially owns 16.76% of shares; GSK plc owns 9.25%.
- Company ended 2025 with $602.1 million in cash and cash equivalents.
- Net loss for 2025 was $(204.4) million.
Financial Impact
Equity plan dilution of 11,000,000 shares represents approximately 5.6% of the 197.2 million shares outstanding as of the record date. CEO total compensation of $12.3 million is heavily equity-weighted ($10.9 million in grant-date fair value).
Risk Factors
- Significant equity dilution if the 11,000,000-share plan increase is approved, adding ~5.6% to the current share count.
- 68% of outstanding stock options are underwater, potentially reducing retention and motivation for employees.
- Net loss of $(204.4) million in 2025 with no approved products; cash runway extends only into Q3 2028 per the filing.
- CEO compensation is heavily weighted toward equity, creating potential for misalignment if the stock price remains depressed.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001193125-26-421806 |
| Document: 0001193125-26-421806-index-headers.html | 0001193125-26-421806 |
| Document: 0001193125-26-421806-index.html | 0001193125-26-421806 |
| Document: 0001193125-26-421806.txt | 0001193125-26-421806 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | DEF 14A | $3.19 $3.13 | ▼ −1.88% | ▼ −0.77% | $3.18 (−0.31%) |
Sep 30, 2026 26d ago | Press Release | $3.70 $3.88 | ▲ +4.86% | ▲ +4.69% | $3.18 (−14.05%) |
Aug 13, 2026 10w ago | Insider Cluster | $5.41 $5.09 | ▼ −5.92% | ▼ −5.44% | $3.18 (−41.22%) |
May 18, 2026 23w ago | Press Release | $6.14 $6.19 | ▲ +0.81% | ▼ −0.23% | $3.18 (−48.21%) |
Apr 28, 2026 25w ago | 8-K | $7.52 $7.05 | ▼ −6.25% | ▼ −6.24% | $3.18 (−57.71%) |
Apr 28, 2026 25w ago | Press Release | $7.52 $7.05 | ▼ −6.25% | ▼ −6.24% | $3.18 (−57.71%) |
Apr 22, 2026 26w ago | Press Release | $7.38 $7.31 | ▼ −0.95% | ▼ −0.55% | $3.18 (−56.91%) |
Apr 15, 2026 27w ago | DEFA14A | $7.32 $7.49 | ▲ +2.32% | ▲ +1.11% | $3.18 (−56.56%) |
Apr 15, 2026 27w ago | 8-K | $7.32 $7.49 | ▲ +2.32% | ▲ +1.11% | $3.18 (−56.56%) |
Mar 26, 2026 30w ago | Press Release | $6.20 $6.37 | ▲ +2.74% | ▲ +4.42% | $3.18 (−48.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers